Recently, the Hainan Provincial Medical Security Bureau issued the “Notice on the Implementation of the Selected Results of the Centralized Procurement of Medical Consumables for the “Six Diseases Co-management” of the Sanming Alliance” (hereinafter referred to as the “Notice”), which will implement the selected results of the centralized procurement of three types of consumables from May 20, 2025. A total of 43 companies were selected in this centralized procurement of three types of consumables. The agreed quantities and bidding prices of some products are as follows: According to the relevant notice issued by the Sanming Procurement Alliance earlier, the procurement varieties and requirements are as follows: It is reported that this centralized procurement quotation divides the products into groups A and B. In the same product category, each applicant can only declare one price, covering all products that meet the application conditions under the product category. Among them, the ...
On May 11, international giant Merck issued a notice stating that due to the impact of the Sino-US trade tariff policy, a temporary surcharge will be imposed on all product orders shipped to China starting from May 12. Merck, as a global technology giant with a profound history, has business in three key areas: life sciences, pharmaceuticals and health, and electronic technology. Since its founding in 1668, Merck, headquartered in Germany, has occupied a pivotal position in the global market with its outstanding technological innovation capabilities and extensive product portfolio. The Chinese market is of great significance to Merck, whose development history in this land can be traced back more than 90 years ago. Currently, Merck has nearly 4,500 employees in China, with a wide range of business layout, including 21 registered companies in Beijing, Shanghai, Wuxi, Suzhou, Nantong, Hong Kong, etc., building a complete industrial chain integrating R&D, production ...
Drugdu.com expert’s response: Record compliance in pharmaceutical enterprises is a core element in safeguarding drug quality, ensuring patient medication safety, and maintaining corporate reputation and market competitiveness. The following provides an in-depth analysis from the perspectives of importance, influencing factors, challenges, and coping strategies: I. The Importance of Record Compliance in Pharmaceutical Enterprises Regulatory Compliance and Legal Liabilities: Pharmaceutical companies must strictly adhere to regulations such as the “Drug Administration Law” and “Good Manufacturing Practice (GMP).” Record compliance is a core requirement of regulatory oversight. Inaccurate or missing records may expose enterprises to severe consequences, including hefty fines, product recalls, or even license revocation. Drug Quality and Safety Assurance: Complete and accurate records form the basis for traceability throughout the entire drug production process. For instance, the compliance of records related to raw material procurement, production processes, and inspection data directly impacts whether drug quality meets standards. Any missing records in any环节 ...
The competition in the GLP-1 track is becoming increasingly fierce, and the game between giants to grab the market is becoming more and more obvious. On May 11th, Eli Lilly and Company released research data on SURMUNT-5, which exploded like a bombshell in the global weight loss drug market. Its new GLP-1/GIP dual receptor agonist, Tilpotide, outperformed Novo Nordisk’s semaglutide in key indicators such as weight loss of 20.2% vs 13.7% and waist circumference reduction of 18.4cm vs 13.0cm. According to the data disclosed by Eli Lilly, in the primary endpoint of the study, telapride achieved a relative weight loss of 1.47 times compared to semaglutide. According to research data based on treatment plan estimation goals, at week 72, the average weight loss rate achieved by telmisartan was 20.2%, while that of semaglutide was 13.7%. The average weight loss of the Tilpotide group was 22.8kg, and the average weight loss ...
On the evening of May 12th, Yuanda Pharmaceutical once again disclosed the new progress of a globally innovative radionuclide coupled drug TLX591 CDx under research. The Phase III clinical trial of this drug in China has been completed with all patients enrolled for administration, and it is planned to submit a new drug application for market launch in China this year. This is the third major innovative research and development progress announced by Yuanda Pharmaceutical since May 6th. From May 7th to May 12th, the stock price of Yuanda Pharmaceutical rose strongly and reached a historical high of HKD 8.95 per share on May 12th. On May 13th, the stock price slightly fell, and as of the close, the stock price was HKD 8.29 per share, with a cumulative increase of 38.4% from May 7th to May 13th. This year, with the recovery of pharmaceutical stocks, the position of innovative ...
WASHINGTON (AP) — U.S. health regulators announced an effort Tuesday to phase out ingestible fluoride supplements sometimes used to strengthen children’s teeth, opening a new front in Health Secretary Robert F. Kennedy Jr.’s effort against a mainstay of dental care. The Food and Drug Administration said it will conduct a scientific review of the children’s products by late October with the aim of removing them from the market. Formally withdrawing medical products requires a lengthy rulemaking process that can take years. Instead, the FDA will ask manufacturers to voluntarily pull their products, according to an administration official. Fluoride tablets and lozenges are sometimes recommended for children and teens at increased risk of tooth decay or cavities because of low fluoride in their local drinking water. Companies also sell drops for babies. FDA Commissioner Marty Makary said the products pose a risk when swallowed because they may interfere with healthy gut ...
In the fast-paced and capital-intensive world of biopharma, early-stage companies face a complex web of challenges—from securing funding and protecting IP to navigating regulatory and commercial pathways. Armando Castro, Partner in the Emerging Companies & Venture Capital practice at Lowenstein Sandler, brings deep legal and strategic expertise to the table, guiding innovative startups through these pivotal moments. In an interview with Pharmaceutical Executive, Castro shares his insights on the current funding environment, trends in biotech dealmaking, and how early-stage life sciences companies can position themselves for long-term success. Pharmaceutical Executive: Are there any unique regulatory or legal risks that investors should be aware of when evaluating companies repurposing GLP-1 drugs for addiction therapy? Armando Castro: There are unique challenges in this space. One of them—perhaps unexpectedly—is the patent issue I mentioned earlier. You might think, “I’m taking an existing substance and entering a new market,” only to discover that repurposing ...
May 13, Tonghua Dongbao, the company announced that it had recently received a drug registration certificate for protamine human insulin injection approved and issued by the National Health Regulatory Agency of Nicaragua (ANRS). Protamine human insulin injection is suitable for type 1 or type 2 diabetes. The main ingredient is human insulin, which is produced through genetic recombination technology. It can promote the uptake and utilization of glucose by tissues such as the liver, muscle and fat, inhibit the decomposition of liver glycogen and gluconeogenesis, and thus lower blood sugar levels. Protamine can slowly release insulin and prolong its duration of action. https://finance.eastmoney.com/a/202505133403178852.html
On May 13, Sinopharm Modern issued an announcement that recently, its wholly-owned subsidiary Sinopharm Rongsheng Pharmaceutical Co., Ltd. received the “Notice of Approval of Drug Supplementary Application” approved and issued by the National Drug Administration, approving Amikacin Sulfate Injection to pass the generic drug quality and efficacy consistency evaluation. The announcement mentioned that the sales of amikacin sulfate injection in public medical institutions across the country will be 233 million yuan in 2024. So far, Sinopharm Rongsheng has invested approximately 4.59 million yuan (unaudited) in research and development for the consistency evaluation of the drug. In the first quarter of 2025, Sinopharm Modern achieved revenue of 2.607 billion yuan and net profit attributable to shareholders of the parent company of 361 million yuan. https://finance.eastmoney.com/a/202505133403270474.html
On the evening of May 11th local time, US President Trump stated on social media that he would sign an executive order at 9 am the next day (9 pm Beijing time on the 12th) with the goal of immediately reducing US prescription drug and medicine prices by 30% to 80%.Image source: Truth Social Trump believes that drug prices in the United States are much higher than in other countries, and the price of the same drug in the United States may be several times that of other countries. This policy mainly includes the implementation of the “most favored nation policy”, allowing the United States to enjoy the same price treatment as the countries with the lowest drug prices in the world, and the US government will renegotiate prices with pharmaceutical companies. If this policy can be implemented, it will greatly reduce the medical burden on the American people, especially ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.